This study aimed to design and synthesize a tumor-responsive nanoparticle-based system for imaging and therapeutic applications of various cancer types.
M-Series MRI. Image Credit: Scintica Instrumentation Inc.
Methods
Manganese oxide nanoparticles (Mn3O4 NPs) were synthesized and modified with an LHRH-targeting peptide or anti-melanoma antibodies (cancer-targeting moieties), as well as an MMP2 cleavable peptide (a possible chemotactic agent). Nanostructured lipid carriers (NLCs) were employed to entrap the BRAF inhibitor vemurafenib and enhance the drug’s cytotoxicity.
The synthesized nanoparticles were studied in vitro for size distribution, stability, drug entrapment, cytotoxicity, and genotoxicity. In vivo studies examined the nanoparticles’ body distribution and ability to enhance MRI signals in mouse melanoma, ovarian, and lung cancer models.
Results
Stable and uniform cancer-targeted nanoparticles (PEGylated water-soluble Mn3O4 NPs and NLCs) were synthesized. No cytotoxicity, genotoxicity, or DNA damage was observed in nanoparticles without an anticancer drug. When vemurafenib was entrapped into the nanoparticles, drug toxicity was significantly enhanced in cancer cells with the targeted V600E mutation.
Nanoparticles containing LHRH and MMP2 peptides exhibited preferential accumulation in primary and metastatic tumors, increasing the MRI signal in mice with melanoma, lung, and ovarian cancers.
Conclusions
The proposed nanoparticle-based systems lay the groundwork for developing an integrated MRI diagnostic and therapeutic approach for treating various cancer types.
Image Credit: Scintica Instrumentation Inc.
Image Credit: Scintica Instrumentation Inc.
References and further reading:
Savla, R., et al. (2014). Tumor-Targeted Responsive Nanoparticle-Based Systems for Magnetic Resonance Imaging and Therapy. Pharmaceutical Research, 31(12), pp.3487–3502. https://doi.org/10.1007/s11095-014-1436-x.
About Scintica Instrumentation Inc.
Scintica Instrumentation Inc., a high value distributor of scientific medical equipment, was created as a joint venture between two companies, Indus Instruments and ONS Projects Inc., both with long standing experience in the medical device instrumentation field. Indus Instruments is an engineering and manufacturing company with excellence in designing and producing sophisticated products for both medical and other high-tech clients in aerospace, chemical and oil and gas industries. ONS Projects Inc. is a life science investment and marketing company built on the foundation of two other successful manufacturing companies in the laboratory instrumentation field,
The principals of the two companies each have more than 25 years of experience of manufacturing, selling and supporting scientists in their research around the world. Our team consists of scientists, applications experts, engineers and sales professionals from a cross section of backgrounds, who excel at simplifying transactions and ensuring that scientists have the best equipment for achieving research excellence.
At Scintica Instrumentation, we distribute for selected manufacturers from all over the world and represent them in multiple countries including the United States, Canada, and Europe, as well as in Asia through a network of authorized sub-distributors.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.